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Abstract
Background: Thermal ablation techniques have become important treatment options for patients with unresectable hepatic
malignancies. Microwave ablation (MWA) is a new thermal ablative technique that uses electromagnetic energy to produce
coagulation necrosis. We report outcomes from the first clinical trial in the United States using MWA and a 915 MHz
generator. Patients and methods: Patients with unresectable primary or metastatic liver cancer were enrolled in a multi-
institutional trial from March 2004 through May 2006. Demographic information, diagnosis, treatment, and outcomes
were documented. Results: Eighty-seven patients underwent 94 ablation procedures for 224 hepatic tumors. Forty-two
ablations (45%) were performed open, 7 (7%) laparoscopically, and 45 (48%) percutaneously. The average tumor size was
3.6 cm (range 0.59.0 cm). Single antenna ablation volumes were 10.0 ml (range 7.814.0 ml), and clustered antennae
ablation volumes were 50.5 ml (range 21.1146.5 ml). Outcome variables were measured with a mean follow-up of 19
months. Local recurrence at the ablation site occurred in 6 (2.7%) tumors, and regional recurrence occurred in 37 (43%)
patients. With a mean follow-up of 19 months, 41 (47%) patients were alive with no evidence of disease. There were no
procedure-related deaths. The overall mortality rate was 2.3%. Conclusions: Microwave ablation is a safe and effective
technology for hepatic tumor ablation. In our study, clustered antennae resulted in larger ablation volumes. Further studies
with histological confirmation are needed to verify clinical results.
Introduction
Options for liver-directed therapy of unresectable
hepatic tumors have expanded in the last decade.
Up to 33% of patients with hepatocellular cancer
(HCC) and up to 20% of patients with metastatic
colon cancer are not candidates for surgical resection
[1,2]. Currently available ablative techniques include
cryotherapy, radiofrequency ablation (RFA), micro-
wave ablation (MWA), laser ablation, high frequency
ultrasonic ablation (HIFU), and ethanol ablation.
RFA is the most widely used technique due to its
availability, efficacy, marketing, recent technical ad-
vances, and low complication rates [3]. However,
RFA can be time-consuming and associated with
higher recurrence rates in larger lesions, particularly
with impedance-based systems [4].
MWA is a new treatment option with several
theoretical advantages over RFA. MWA has an
improved convection profile, consistently higher in-
tratumoral temperatures, larger ablation volumes,
faster ablation times, and the option of using multi-
ple antennae simultaneously [5]. MWA uses electro-
magnetic energy to agitate adjacent water molecules.
Thermal energy is released due to molecular friction,
allowing nearby tumor cells to undergo coagulation
necrosis. Recent technical advances in MWA include
the reduction of feedback and an increase in energy
delivery by tuning antennae to the dielectric proper-
ties of liver tumors [6]. MWA antennae and gen-
erators are similar to RFA; however, they use a
different part of the electromagnetic spectrum. Like
RFA, MWA instruments have been developed for
percutaneous, laparoscopic, and open procedures
[7].
The use of microwave technology in Japan began in
the late 1980s; however, it was not widely adopted
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due to small ablation diameters obtained with single
2.4 GHz needle antenna [8,9]. With the discovery
that larger coagulation diameters could be obtained
by clustering the antennae, microwave technology
became more clinically relevant and was reported to
be useful for larger tumors [10,11]. However, MWA is
not widely available in the USA, and experience with
this approach is limited. A recent Phase I clinical trial
evaluated treatment with multiple microwave anten-
nae in patients undergoing subsequent liver resection.
The study concluded that clustering multiple needle
antennae causes a synergistic effect and results in
mean maximum ablation diameters of 5.5 cm and
average ablation zone volumes of 50.8 cm3 [7]. The
purpose of this trial was to evaluate the outcomes of
patients with unresectable liver tumors after under-
going treatment with MWA.
Patients and methods
Institutional Review Board approval was obtained for
a multi-institutional study from March 2004 through
May 2006. Patients with unresectable primary or
metastatic liver cancer were eligible for enrollment.
Data regarding patient demographics, diagnosis, and
type of procedure were collected. Percutaneous,
laparoscopic, and open procedures (Figure 1) were
included. All tumors were localized and measured
using intraoperative ultrasound or CT fluoroscopy.
Clustered and single microwave antennae were used
for ablations at a power of 45 W for 10 min using a
915 MHz microwave generator (VivaWaveTM System,
Valleylab, Boulder, CO, USA) (Figure 2) for each
needle antenna (Figure 3). Patients were imaged
within 1 month after the procedure and every 4
months for 2 years thereafter. Outcome variables
included morbidity, mortality, technical success, local
tumor control, ablation size, and recurrence.
Results
Eighty-seven patients were enrolled in the study; 47%
male and 53% female. The average age was 67 years
(range 3792). Diagnoses are listed in Table I. The
most common indications for liver-directed therapeu-
tic ablation were colorectal metastases (38%) and
HCC (26%).
There were 94 ablation procedures for 224 tumors.
Forty-two ablations (45%) were performed open, 7
(7%) laparoscopically, and 45 (48%) percutaneously.
The average tumor size was 3.6 cm (range 0.59.0 cm).
Twenty-two lesions were4 cm. Mean single antenna
ablation volumes were 10.0 ml (range 7.814.0 ml),
and clustered antennae ablation volumes were 50.5 ml
(range 21.1146.5 ml). Outcome variables were mea-
sured with a mean follow-up of 19 months.
Unexpected residual disease was found in five
patients. Expected residual disease was found in three
patients. Local recurrence at ablation sites occurred in
6 (2.7%) tumors and regional recurrence was noted in
37 (43%) patients. Procedure-related complications
are listed in Table II. Cancer status at follow-up is
listed in Table III. With a mean follow-up of 19
months, 41 (47%) patients were alive with no
evidence of disease. There were no procedure-related
Figure 1. Open microwave liver ablation.
Figure 2. Microwave generators.
Figure 3. Microwave antenna.
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deaths. Two deaths unrelated to the procedure
occurred several months after the ablations, resulting
in an overall mortality rate of 2.3%. One death was
due to a myocardial infarction and the other to a
cerebrovascular ischemic event.
Discussion
Surgical resection of HCC and colorectal cancer
metastases has been shown to increase 5-year survival
and disease-free survival for patients with resectable
lesions [7,1214]. Unfortunately, some patients have
unresectable disease due to inadequate hepatic re-
serve or extensive disease. Liver-directed therapy for
patients with unresectable disease includes a wide
range of ablation techniques including RFA, MWA,
laser ablation, high frequency ultrasound ablation,
cryoablation, and ethanol ablation. RFA is the most
widely used and best studied technique worldwide. It
is considered first-line treatment for small (B3 cm)
unresectable HCC [15,16]. Controversy exists as to
which new technology offers the most advantages over
RFA. MWA is one of the most recent and exciting
advances in the field of thermoablative technology
and, similar to RFA, can be performed open, lapar-
oscopically, or percutaneously. The potential advan-
tages of microwave technology compared with RFA
include consistent production of higher intratumoral
temperatures, faster ablation times, improved convec-
tion profiles, larger tumor ablation volumes, the use of
multiple antennae, and less procedural pain
[6,10,17,18]. Another advantage of MWA is that it
does not require the use of grounding pads, which
decreases the time required for patient preparation.
Thermal ablative techniques for unresectable hepa-
tic lesions have been described previously. Taura and
colleagues [19] reported outcomes of more than 600
patients after hepatic resection for HCC. They
observed, in a multivariate analysis, that application
of local thermal ablative therapies was an independent
favorable prognostic factor for this patient population
[19]. Recent studies have evaluated the use of MWA
in HCC. Lu and colleagues [20] reviewed surgical
resection versus radiofrequency and MWA for early
stage HCC. They reported that RFA and MWA had
equivalent 3-year survival outcomes and local effec-
tiveness compared with surgical resection, and re-
commended that both thermoablative techniques be
considered a first-line treatment modality for early
stage HCC [20]. Dong and colleagues [21] reported
the efficacy of MWA in early HCC with complete
tumor necrosis and a low complication rate in 96% of
patients. Contrary to these results, Wakai and collea-
gues [22] retrospectively reviewed 149 patients with
HCC tumors  4 cm with a median follow-up of 69
months. They concluded that hepatectomy provided
significantly better local control and improved long-
term survival over various ablation techniques, in-
cluding percutaneous ethanol ablation, RFA, and
MWA [22].
MWA has also been evaluated previously as treat-
ment for colorectal liver metastases. Liang and
colleagues [23] examined the long-term effects of
ultrasound-guided MWA for colorectal metastatic
liver lesions. With an average follow-up of 29 months,
they reported significantly improved long-term survi-
val in patients with well-differentiated tumors mea-
suring 3.0 cm or less and no local recurrence or new
colorectal metastases after MWA therapy [23]. Shi-
mizu and colleagues [24] reviewed combined hepatic
resection plus MWA in patients with multiple bilobar
liver metastases from colon cancer and reported that
hepatic resection plus MWA was equally effective to
hepatic resection alone.
Most clinical trials examining the safety and efficacy
of MWA have been done outside of the US with 2.4
GHz generators. In 2003, a new 915 MHz MWA
system was engineered in the US [6]. We report results
from a clinical series of MWA in the US. Similar to
previous studies, we found that HCC and metastatic
colon cancer are the most common indications for
MWA use. We also observed MWA to be a flexible
thermoablative technique, with no increased difficulty
with procedures performed open, laparoscopically, or
percutaneously. We and other authors have reported
that larger ablations can be obtained with multiple or
clustered microwave antennae [7,10,25]. Simon and
colleagues [7] reported the feasibility of using multiple
microwave antennae simultaneously in the treatment
of liver tumors with an average ablation zone volume
Table II. Procedure-related complications in 87 patients.
Complication No. of patients
Skin burns 3
Wound breakdown 2
Re-admission (nausea, over-sedation) 2
Pain requiring termination of procedure 1
Fluid collections 2
Persistent postoperative ileus 2
Subscapular hematoma 1
Fever/staphylococcal infection 1
Table I. Indications for ablation and diagnoses in 87 patients.
Indication for ablation No. of patients (%)
Colorectal metastasis 33 (37.93)
Hepatocellular carcinoma 23 (26.44)
Breast metastasis 11 (12.64)
Carcinoid metastasis 8 (9.19)
Renal metastasis 3 (3.45)
Lung metastasis 3 (3.45)
Adrenal metastasis 1 (1.15)
Esophageal metastasis 1 (1.15)
Gallbladder metastasis 1 (1.15)
Gastric metastasis 1 (1.15)
Melanoma metastasis 1 (1.15)
Ovarian metastasis 1 (1.15)
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of 50.8 cm2. We also found that clustering antennae
resulted in higher ablation volumes  50.5 ml com-
pared with 10.0 ml for a single antenna. The feasibility
of using MWA for larger tumors was demonstrated in
our study, as the average tumor size was 3.6 cm. MWA
was also used in 23 lesions that were4 cm. While this
technology can achieve higher ablation volumes with
clustering of antennae, it is important to remember
that increasing size of tumors may adversely affect the
efficacy of MWA as well as other thermoablative
techniques. This was evidenced by a study by Liang
and colleagues [26], who reviewed prognostic factors
of 288 patients who underwent MWA for HCC and
showed improved survival in treatment of single
lesionsB4 cm for patients with Childs-Pugh class A
cirrhosis.
Another attractive characteristic of MWA and
thermal ablation techniques in general is the low
morbidity and mortality associated with the proce-
dure. Dong and colleagues [21] reported three severe
complications and one unrelated death from a pul-
monary infection in 216 patients treated with MWA
for early stage HCC. We also report a low morbidity
rate with a total of 14 (16%) complications, the most
common being skin burns, which occurred in 3
patients. In addition, hypothermia, disseminated in-
travascular coagulation (DIC), and hemolysis, which
can occur in cryoablation, did not occur in our study
and traditionally have not been reported in patients
undergoing MWA.
In conclusion, MWA is a safe and effective technol-
ogy for hepatic tumor ablation. At a mean follow-up
of 19 months, 47% of patients were alive with no
evidence of disease, and local recurrence rates and
regional recurrence rates were 2.7% and 43%, re-
spectively. Our study provides additional clinical data
that clustered antennae result in larger ablation
volumes. Histological confirmation and comparison
to real-time 3-dimensional Doppler ultrasound are
needed to verify clinical results. Further trials with
long-term follow-up and controlled trials comparing
various types of liver-directed thermoablative tech-
nologies in vivo are needed.
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